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Abstract: Background: Ganoderma fungus is rich in terpenoids. These compounds are known for
their anti-hyperglycemic activities. However, the study of terpenoids as the secondary metabolite
from Ganoderma as a dipeptidyl peptidase-4 (DPP-4) inhibitor remains unexplored. In addition, we
examined the α-glucosidase inhibition activity. Objective: This study aimed to isolate the major
terpenoid from non-laccate Ganoderma and examined its inhibitor activity on DPP-4 and α-glucosidase
enzymes, and its interaction. Methods: The compound was isolated using column chromatography
from Ganoderma australe. The structure of the isolated compound was confirmed by 1H and 13C
nuclear magnetic resonance spectroscopy, while the inhibitory activity was evaluated using an
enzymatic assay. The interaction of the isolated compound with DPP-4 and α-glucosidase enzymes
was investigated using an in silico study. Results: The isolated compound was identified as stellasterol;
IC50 values for DPP-4 and α-glucosidase inhibitor were 427.39 µM and 314.54 µM, respectively. This
study revealed that the inhibitory effect of stellasterol on DPP-4 enzyme is through hydrophobic
interaction, while the α-glucosidase enzyme is due to the interaction with six amino acids of the
enzyme. Conclusion: Stellasterol is the major component of the steroid from G. australe. Enzyme
inhibitory assay and in silico study suggest that stellasterol may contribute antidiabetic activity with
a mechanism closer to acarbose rather than to sitagliptin.
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1. Introduction
Ganoderma is a cosmopolitan woody polypore fungus with a broad distribution in tropical regions,
including Indonesia. Ganoderma comprises two subgenera based on the pileus surface, the shiny
or laccate subgenus (G. lucidum complex~Ganoderma), and the non-shiny or non-laccate subgenus
(G. applanatum complex~Elfvingia) [1]. The fruit bodies of Ganoderma lucidum have been used for
diabetes mellitus treatment as food and folk medicine [2–4]. Moreover, Ganoderma is classified as
a nutraceutical mushroom similar to cordyceps, shiitake, maitake, chaga, and others for herbal
remedies [5]. In contrast, the non-laccate subgenus of Ganoderma has received less attention for medical
purposes [6].
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Antidiabetic drugs that have been released on the market have action mechanisms such as
stimulating insulin secretion, delaying digestion and absorption, improving peripheral glucose uptake,
suppressing hepatic glucose production, and increasing the sensitivity of insulin receptors [7,8]. The
drawbacks of these antidiabetic drugs are hypoglycemia and weight gain [9]. A novel therapeutic
approach for diabetes mellitus treatment with weight neutrality uses incretin hormones [8].
Incretin hormones are secreted from the gut and can be classified into two predominant hormones,
i.e., glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Food
ingestion stimulates the secretion of incretin hormones, then these hormones induce insulin release
from pancreatic β-cells, which further reduce the blood glucose [10]. In addition, GLP-1 has some
advantages, such as pancreatic β-cell protection, reducing appetite in the brain, and slowing gastric
emptying [10,11]. However, the half-life of GLP-1 is short at approximately 2 min, due to the rapid
metabolism by the enzyme DPP-4 [12]. According to their structures, DPP-4 inhibitors fall into two
categories: peptidomimetic and non-peptidomimetic. Sitagliptin was the first peptidomimetic DPP-4
inhibitor launched, followed by tenegliptin, gemigliptin, anagliptin, and evogliptin during 2012 to
2015. Retagliptin, denagliptin, and gosogliptin are peptidomimetic DPP-4 inhibitors under clinical
trials. The peptidomimetic DPP-4 inhibitors cover inhibitors structurally similar to peptide or amide
bonds, while non-peptidomimetic inhibitors do not require peptide scaffolds. Since the peptidomimetic
DPP-4 inhibitors were related to enzymatic cleavage, the non-peptidomimetic inhibitors are now
being explored. Linagliptin, anagliptin, omarigliptin, and trelagliptin are non-peptidomimetic DPP-4
inhibitors that have been launched, while carmegliptin and imigliptin are under clinical trials [13–17].
The α-glucosidase inhibitors show minimal effects in inducing hypoglycemia and in weight loss.
The main downside of α-glucosidase inhibitors is abdominal discomfort due to its mechanism in
preventing the degradation of polysaccharides into monosaccharides. The undigested polysaccaharides
are digested by bacteria in the colon, thus inducing bloating and diarrhea [18].
This study was aimed to isolate major terpenoid compounds from non-laccate Ganoderma. In vitro
and in silico assays were conducted to understand the inhibition profile of this compound against
DPP-4 and α-glucosidase enzyme.
2. Materials and Methods
2.1. Materials
Fresh Ganoderma australe was harvested in September 2016 in Bogor Botanical Gardens. The
voucher specimens were deposited in Bogor Botanical Gardens (BO22952) and DNA identification
was done with GenBank code MK131240. Silica gel 60 (0.063–0.200 mm) for column chromatography
and all organic solvents were purchased from Merck. Human DPP-4 enzyme (Product number:
D4943), glycine-proline-p-nitroaniline (CAS 103213-34-9) as the chromogenic substrate DPP-4, and
Trizma® HCl as the DPP-4 buffer were purchased from Sigma. The sodium dihydrogen phosphate
monohydrate (NaH2PO4.H2O) and disodium hydrogen phosphate (Na2HPO4) as α-glucosidase buffer
were purchased from Merck. Para-nitrophenylα-D-glucopyranoside (EC. 223-189-3 and CAS 3767-28-0)
and α-glucosidase from Saccharomyces cerevisiae (EC. 232-604-7 and CAS 9001-42-7) were obtained from
Sigma. The absorbance was measured with an Infinite® M200 Pro microplate reader.
2.2. Extraction and Isolation
The dried and pulverized fruit bodies of Ganoderma australe (3 kg) were extracted exhaustively
with hexane using a Soxhlet apparatus. The evaporated hexane extract was subjected to column
chromatography to yield seven fractions (A–G) with a stepwise gradient elution of hexane-ethyl
acetate (100:0→0:100 v/v) solvent. Fraction E (1.5 g) was further purified using silica gel column
chromatography eluted with hexane-ethyl acetate (100:0→ 0:50 v/v) to yield five subfractions (E1-E5).
Subfraction E3 was further purified by washing with hexane to obtain the isolated compound (Figure 1).
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2.3. Instrumentation
The spectra of 1H and 13C-NMR of the isolated compound were recorded on an Agilent
spectrometer (13C:125 MHz; 1H:500) with tetramethylsilane (TMS) as the internal standard. The
spectrum was measured using deuterated chloroform (CDCl3) as a solvent.
2.4. In Vitro Study of DPP-4 Inhibition
Ten milligrams of the isolated compound were diluted in 10 mL Trizma® HCl buffer at pH 7.5
(50 mM). Various concentrations of samples at 60, 125, 250, and 500 µM and sitagliptin as positive
control at 0.5, 1, 2, 4, and 8 µM were used. The assay was performed according to Chakrabarti et al. [19]
and Al-Masri et al. [20]. Each well contained a mixture of 15 µL of DPP-4 enzyme (0.05 U/mL) and
35 µL of standard or sample. The mixture was incubated at 37 ◦C for 10 min as the first incubation.
Subseque tly, 50 µL of substrate 0.2 mM were added to this mixture, f llowed by the second incubation
at 37 ◦C for 30 min. Finally, to stop the reaction, 25 µL acetic acid 25% were added. The absorbance
was measured at λ 405 nm and the inhibition activity was calculated by the following formula:
% Inhibition = [(Abs control − Abs standard or sample)/Abs control] × 100
2.5. In Vitro Study of α-Glucosidase Inhibition
Ten milligrams of the isolated compound were diluted in 10 mL phosphate buffer at pH 6.9.
Various concentrations of the isolated compound and 60, 125, 250, and 500 µM acarbose were used.
The assay was performed according to Munim et al. [21] with slight modifications. The α-glucosidase
enzyme was dissolved in 100 mL phosphate buffer at pH 6.9. Phosphate buffer was prepared by
dissolving 1.42 g Na2HPO4 and 1.38 g NaHPO4.H2O in 100 mL containing 200 mg bovine serum
albumin. Each well contained a mixture of 10 µL of standard or sample and 25 µL of substrate 0.625 mM,
followed by first incubation at 37 ◦C for 10 min. Subsequently, 25 µL of an enzyme (0.05 U/mL) were
added and incubated for 15 min at 37 ◦C. One hundred milliliters of sodium carbonate 0.2 mM were
used to stop the enzymatic reaction. The absorbance was measured at λ 405 nm and the inhibition
activity was calculated with the same formula used to measure DPP-4 inhibition.
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2.6. In Silico Study
Crystallography of human dipeptidyl peptidase-4 (PDB: 1X70) complex with sitagliptin and
α-glucosidase from Saccharomyces cerevisiae (PDB: 3W37) complex with acarbose were obtained from
the Protein Data Bank. The structure of the isolated compound was downloaded from the PubChem
database. Preparation of the ligand and the protein was performed using the AutoDock Tools 1.5.6
program (ADT). The interaction pattern between the ligand and the receptor was studied using the
Lamarckian genetic algorithm (LGA). Docking studies were carried out using AutoDock Tools v.1.5.6
embedded in MGL Tools [22]. The grid box of sitagliptin was adjusted at x 41.376; y 51.2; z 36.2 and the
grid box of acarbose was adjusted at x 0.699; y −1.87; z −23.212.
2.7. Statistical Analysis
All inhibitory data are expressed as mean ± SD (n = 3). The IC50 data were calculated using
GraphPad Prism 8.0.1 software free trial with non-linear regression sigmoidal dose-response.
3. Results and Discussion
3.1. Structure Elucidation
The 1H NMR spectrum of the isolated compound clearly showed six methyl signals at δ 0.54 (3H,
s, H-18); 0.79 (3H, s, H-19); 1.01 (3H, d/s, J = 5.5 Hz, H-21); 0.91 (3H, d, J = 5 Hz, H-24”); 0.81 (3H, d,
J = 15 Hz, H-26); 0.81 (3H, s, H-27) ppm. The 13C-NMR revealed the presence of 28 carbon signals
ascribed to six methyls at δ 12.1 (C-18); 13.1 (C-19); 21.2 (C-21); 17.7 (C-24”); 19.8 (C-26); 20.1 (C-27)
ppm, eight methylenes at δ 37.3 (C-1); 31.6 (C-2); 38.1 (C-4); 29.8 (C-6); 21.7 (C-11); 39.6 (C-12); 23.0
(C-15); 28.2 (C-16) ppm, and eleven methines at δ 71.2 (C-3); 40.6 (C-5); 117.1 (C-7); 49.6 (C-9); 55.3
(C-14); 56.1 (C-17); 40.4 (C-20); 135.9 (C-22); 132.1 (C-23); 43.0 (C-24); 33.2 (C-25) ppm. It also showed
the presence of two double bonds signals at δ 117.6 (C-7); 132.1 (C-23); 135.9 (C-22); and 139.7 (C-8)
ppm (Figure 2). By comparison with published NMR data, the isolated compound was identified as
stellasterol [23,24].
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Figure 2. Stellasterol isolated from Ganoderma australe. 
3.2. Assay of DPP-4 and α-Glucosidase Inhibition 
Our previous study showed that hexane extract had the highest activity to inhibit α-glucosidase 
enzyme followed by ethyl acetate and methanol extract (data not shown). These results suggest that 
there are responsible compounds as α-glucosidase inhibitor present in hexane extract. Based on 
extraction-guided activity, we decided to isolate the hexane extract then examined two different 
inhibition enzyme mechanisms. Our isolation revealed that stellasterol was the major compound 
from the hexane extract. 
Stellasterol showed DPP-4 inhibition activity with IC50 at 427.39 µM, while sitagliptin as the 
positive control had IC50 0.73 µM. Sitagliptin showed much stronger activity against DPP-4 enzyme 
than stellasterol. As the α-glucosidase inhibitors, stellasterol and acarbose were 314.54 µM and 
207.87 µM, respectively. By comparing the standards, it seems that the activity of stellasterol was 
more similar to acarbose rather than sitagliptin as a hypoglycemic agent. These results were studied 
using in silico interaction. 
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3.2. Assay of DPP-4 and α-Glucosidase Inhibition
Our previous study showed that hexane extract had the highest activity to inhibit α-glucosidase
enzyme followed by ethyl acetate and methanol extract (data not shown). These results suggest
that there are responsible compounds as α-glucosidase inhibitor present in hexane extract. Based
on extraction-guided activity, we decided to isolate the hexane extract then examined two different
inhibition enzyme mechanisms. Our isolation revealed that stellasterol was the major compound from
the hexane extract.
Stellasterol showed DPP-4 inhibition activity with IC50 at 427.39 µM, while sitagliptin as the
positive control had IC50 0.73 µM. Sitagliptin showed much stronger activity against DPP-4 enzyme
than stellasterol. As the α-glucosidase inhibitors, stellasterol and acarbose were 314.54 µM and
207.87 µM, respectively. By comparing the standards, it seems that the activity of stellasterol was more
similar to acarbose rather than sitagliptin as a hypoglycemic agent. These results were studied using
in silico interaction.
Sci. Pharm. 2019, 87, 21 5 of 9
3.3. Stellasterol In Silico Study for DPP-4 Enzyme
The in silico approach was performed to predict the protein–ligand binding pose between
stellasterol, either with DPP-4 or α-glucosidase enzyme. The root mean square (RMSD) of 0.50 was
gained for stellasterol with the native ligand extracted from the DPP-4 enzyme, while RMSD score for
stellasterol in comparison to the origin of the α-glucosidase enzyme was 1.18 . The most negative
docking score was chosen to be used in analyzing pose interaction between ligand and receptor [25].
Docking simulation of stellasterol into the DPP-4 cavity revealed that the main interaction was
hydrophobic. Stellasterol filled the hydrophobic cavity involving Trp659, Tyr547, Tyr631, Tyr662,
Tyr666, Phe357, Val656, and Val711 (Table 1). Marvanita and Patel [26] suggested that these amino acid
residues were the natural hydrophobic cavity of human DPP-4 (Table 2). Furthermore, linagliptin had
pi–pi interactions in addition to Tyr547 and Trp629 residues compared to alogliptin. These additional
interactions are believed to be the leading factor to elevate the potential for linagliptin compared
to alogliptin [27]. Arulmozhiraja et al. [28] proposed that the interaction with Glu206 and Glu205
through hydrogen bonds in sitagliptin, alogliptin, linagliptin, and teneligliptin inhibitors are the first
specifications for DPP-4 inhibitor beside Tyr547, Trp629, Tyr666, and Phe357. In addition, the interaction
with S2’ is important and interaction with the S2 extensive can elevate not only the potency but also
the selectivity. Furthermore, larger inhibitors that fulfill the hydrophobic cavity could elevate the
inhibitory potential and stabilize the ligand–receptor complex [28,29]. Stellasterol only interacts with
Tyr547 in pi–alkyl interaction and other interactions mostly through hydrophobic bonds, suggesting its
lower capacity to bind DPP-4 enzyme.
Kalhotra et al. [30,31] examined the profile for the addition of hydroxyl groups to inhibit the DPP-4
enzyme. Their results showed that galangin (a flavonoid with two hydroxyl groups) gives higher
inhibition than chrysin (a flavonoid with two hydroxyl groups). Saleem et al. [32] also revealed that
quinovic acid has an IC50 value of 30.7 µM, whereas the addition of two glucose moieties in quinovic
acid elevate the activity (IC50 23.5 µM).
Stellasterol has only one free hydroxyl group at C-3; perhaps this is caused by the lower inhibition
of the DPP-4 enzyme in comparison to the previously structure. Stellasterol, a steroid derivative, has a
non-polar structure in nature exposing domination of alkyl and proton aliphatic groups. Conversely,
sitagliptin as the positive control contains fluoro and amine capable of forming hydrogen bonds with
some amino acids in the DPP-4 cavity. A hydroxyl group of stellasterol interacts through hydrogen
bonding with amino acid Tyr585 in the DPP-4 pocket. This amino acid Tyr585 is a different type
to the amino acids that bind with sitagliptin, Glu205, Glu206, Arg125, Arg358, and Asn710. The
hexane extract showed higher inhibition of DPP-4 enzyme than stellasterol, indicating the activity
against DPP-4 enzyme may not be contributed by stellasterol as the major isolate. According to
Arulmozhiraja et al. [28], stellasterol fulfills the second and third specifications for DPP-4 inhibitor.
3.4. Stellasterol In Silico Study for α-Glucosidase Enzyme
The docking result revealed that acarbose, an oligosaccharide, is surrounded by many hydroxyl
groups that are able to form a hydrogen bond with amino acid residues, such as Arg552, Asp568,
Asp357, His626, Asp232, Asn237, and Ala234 (Figure 3).
In the α-glucosidase cavity, a hydroxyl group position at C-3 of stellasterol interacted with Asn237
through a hydrogen bond similar to acarbose as a positive control. Tagami et al. [33] proposed that
Asn237 was one of the residues that play a role in the long-chain specificity inside the N-loop. This
interaction possibly has a role in increasing the activity of stellasterol against α-glucosidase rather
than DPP-4 enzyme. In addition, stellasterol binds with the same two amino acids Trp329 and Phe601,
similar to acarbose in the hydrophobic pocket. Stellasterol also binds with His626, Ala234, and Met470
in pi–alkyl interaction (Table 3).
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Several terpenoid compounds have been tested as α-glucosidase inhibitors, including ursolic acid,
3β-hydroxy-11-ursen-28,13-olide, and ursonic acid. These compounds demonstrated IC50 8.38, 203.76,
and 100.99 µM. Those compounds showe higher inhibitory activity compared to stellasterol. These
might be due to the presence of carbonyl or the additional hydroxyl groups, or the carboxylic acid
group, which leads to the stronger interaction with α-glucosidase enzyme [34].
Four triterpenoids fro Psidium guajava leaves, namely trihydroxyopsidiumlanostenoic acid,
12β-hydroxypsidiumlanoste oic acid, psidiumlanostenoic acid glucoside, and psidiumlanostenoic
acid, as shown in Figure 4, have been tested in vivo for antidiabetic activity. The administration of 50
mg/kg of these isolate compounds for 1 week in diabetic rats model showed blood glucose levels of
142.50, 154.50, 165.67, and 172.17 mg/dL, respectively. However, the normal control rat and the diabetic
control rat showed 87.66 and 327.33 mg/dL blood glucose levels after 1 week [35].
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4. Conclusions 
The in silico approach helps one to understand and support the in vitro result. According to in 
vitro and in silico results, stellasterol was more likely well-fitted as an α-glucosidase inhibitor rather 
than a DPP-4 inhibitor. 
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Table 1. Interaction of stellasterol and sitagliptin with the binding pocket of the human DPP-4 enzyme.
Ligand Hydrogen Bond Hydrophobic Bond
Glu206 Glu205 Arg358 Arg125 Asn710 Tyr585 Tyr631 Tyr547 Tyr666 Tyr662 Val711 Val656 Trp659 Phe357
Stellasterol - - - - - + pi–alkyl pi–alkyl pi–alkyl pi–alkyl Alkyl–alkyl Alkyl–alkyl pi–alkyl pi–alkyl
Sitagliptin + + + + + - - - pi-pi pi-pi - - - pi–pi
Table 2. Amino acid residues in the active site of the DPP-4 enzyme [28].
Amino Acid Residues
Pocket
S2’ S1’ S1 S2 S2 Ext
Trp629 Tyr547 Tyr666 Arg125 Phe357
His740 Tyr631 Ser630 Arg669 Arg358
Ser630 Phe357 Val656 Glu205 Ser209
Tyr547 Pro550 Trp659 Glu206 Val207
Tyr666 Tyr662 Phe357
Val711 Arg358
Asn710
Table 3. Interaction if stellasterol and acarbose with the binding pocket of the α-glucosidase enzyme.
Ligand Hydrogen Bond Hydrophobic Bond
Arg552 Asp568 Asp367 His626 Asp232 Asn237 Ala234 Ile358 Ile233 Ile396 Trp467 Trp329 Trp432 Trp329 Phe601 Phe236 Ph3476 Met470
Stellasterol - - - pi–alkyl - + pi–alkyl + - + - + + - + + - pi–alkyl
Acarbose + + + + + + + - - - - + - - + - - +
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4. Conclusions
The in silico approach helps one to understand and support the in vitro result. According to
in vitro and in silico results, stellasterol was more likely well-fitted as an α-glucosidase inhibitor rather
than a DPP-4 inhibitor.
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